T3d Therapeutics Inc., of Research Triangle Park, N.C., which is developing T3D-959, an orally administered treatment for Alzheimer's disease (AD), received a grant expected to total $9 million over four years from the National Institute on Aging (NIA), part of the NIH, to help fund a phase II study with the compound, described as a metabolic-focused AD drug treatment.